# LyGenesis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lygenesis

- Industry: Biotechnology
- Headquarters: Pittsburgh, US
- Website: www.lygenesis.com/
- Total disclosed funding: $8.7M
- Latest round: Series A (Oct 5, 2023)
- Investors on record: 2

## About

Based in the US, LyGenesis, Inc. specializes in innovative cell therapies that transform organ transplantation, addressing critical medical needs in patients with Type 1 diabetes and end-stage liver and renal diseases.LyGenesis Inc., founded in 2017 in Pittsburgh, US, focuses on developing advanced cell therapies. The company has not undergone any major pivots since its inception. It was co-founded by Michael Hufford and Paulo Fontes. Recently, the company raised USD 8.731 mn in a Series A funding round led by Prime Movers Lab and participated by Juvenescence Therapeutics Limited, bringing their total amount raised to USD 8.731 mn. The latest funding round occurred on October 5, 2023 and has led to a current company valuation of USD 46.999 mn.LyGenesis specializes in pioneering cell therapies that address significant unmet medical needs, particularly in the areas of Type 1 diabetes and end-stage liver and renal diseases. The company utilizes the patient’s lymph nodes as bioreactors to cultivate functioning ectopic organs, allowing a single donated liver to potentially treat multiple patients suffering from end-stage liver disease. The outpatient procedure to engraft these therapies is performed via endoscopic ultrasound, significantly reducing medical risks and costs compared to traditional organ transplants. LyGenesis primarily serves markets in North America and Europe, partnering with healthcare providers focused on advanced regenerative medicine.LyGenesis generates revenue through its clinical-stage cell therapy products designed for hospitals and specialized medical centers. Their transaction model includes partnerships with healthcare providers who integrate these therapies into treatment protocols for life-threatening conditions. Revenue is realized through agreements that involve direct sales or collaborative clinical trials, reflecting the value of their transformative treatments to improve patient outcomes in critical organ failure scenarios.In October 2023, LyGenesis Inc. raised USD 8.73 mn in Series A funding to complete its Phase 2a clinical trial (ClinicalTrials.gov Identifier: NCT04496479) and advance its pipeline of cell therapies. The company plans to leverage this funding to support the development of new products targeting unmet medical needs. Additionally, there are intentions to expand into new geographic markets in North America and Europe, enhancing accessibility for patients in need of organ replacement therapies.

## Funding rounds

- Series A, Oct 5, 2023, $8.7M — Juvenescence Therapeutics Limited, Prime Movers Lab

## Investors

- Juvenescence Therapeutics Limited — Series A
- Prime Movers Lab (https://capitalatlas.ai/funds/prime-movers-lab) — Series A